trial

Biomarker Study of Acamprosate in Schizophrenia

NCTId NCT00688324
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 4 · Completed
Enrollment 36 (actual)
Sponsored by University of Maryland, Baltimore County
Primary completion 2012-02
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 4
Status
Completed
Enrollment
36 (actual)
Study type
Interventional
Allocation
Na
Model
Single Group
Masking
None
Start
2008-06
Primary completion
2012-02
Eligibility
ALL · 18 Years · 55 Years

Interventions & indications

Drugs
Acamprosate

Sponsors

University of Maryland, Baltimore CountyLead Sponsor
National Alliance for Research on Schizophrenia and DepressionCollaborator
National Institute on Alcohol Abuse and Alcoholism (NIAAA)Collaborator

Investigators

1
Bernard A Fischer, M.D.Principal Investigator

Sites

4 total
Baltimore, United StatesBaltimore, United StatesBaltimore, United StatesBaltimore, United States

Facts & assertions

4 sourced
Enrollment
36
Phase
PHASE4
Primary Completion Date
2012-02
Status
COMPLETED
relationships
The graph out of here
drug
Acamprosate
drug
lead_sponsor
University of Maryland, Baltimore County
company
collaborator
National Alliance for Research on Schizophrenia and Depression
company
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
company
indication
Schizophrenia
indication
Schizoaffective Disorder
indication
Schizophrenia
indication
investigator
Bernard A Fischer, M.D.
person